Search research articles
Contact Us
Filters
Showing results (1-10 of 5) with videos related to
Page
of 1
Sort By:
Nature Reviews. Cancer
|
March 21, 2008
The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy
Isabel M Chu, Ludger Hengst, Joyce M Slingerland
Cell Cycle (Georgetown, Tex.)
|
May 20, 2011
BMI1 suffers a degrading experience
Mark Hoenerhoff, Isabel M Chu, Jeffrey E Green
Plos One
|
April 12, 2013
Expression of GATA3 in MDA-MB-231 triple-negative breast cancer cells induces a growth inhibitory response to TGFß
Isabel M Chu, Wei-Chu Lai, Olga Aprelikova, et al.
Scientific Reports
|
August 23, 2016
Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential
Jason J Lohmueller, Shuji Sato, Lana Popova, et al.
Breast Cancer Research : BCR
|
July 21, 2012
Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer
Christina N Bennett, Christine C Tomlinson, Aleksandra M Michalowski, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 5) with videos related to
Sort By:
Page
of 1
Nature Reviews. Cancer
|
March 21, 2008
The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy
Isabel M Chu, Ludger Hengst, Joyce M Slingerland
Cell Cycle (Georgetown, Tex.)
|
May 20, 2011
BMI1 suffers a degrading experience
Mark Hoenerhoff, Isabel M Chu, Jeffrey E Green
Plos One
|
April 12, 2013
Expression of GATA3 in MDA-MB-231 triple-negative breast cancer cells induces a growth inhibitory response to TGFß
Isabel M Chu, Wei-Chu Lai, Olga Aprelikova, et al.
Scientific Reports
|
August 23, 2016
Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential
Jason J Lohmueller, Shuji Sato, Lana Popova, et al.
Breast Cancer Research : BCR
|
July 21, 2012
Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer
Christina N Bennett, Christine C Tomlinson, Aleksandra M Michalowski, et al.
Page
of 1